{"id":"NCT01195662","sponsor":"AstraZeneca","briefTitle":"A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2010-09-06","resultsPosted":"2014-05-23","lastUpdate":"2016-12-29"},"enrollment":2245,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["BMS-512148","Farxigaâ„¢"]},{"type":"DRUG","name":"Placebo matching Dapagliflozin","otherNames":[]}],"arms":[{"label":"Dapagliflozin 10 mg","type":"EXPERIMENTAL"},{"label":"Placebo matching Dapagliflozin","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting enzyme inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB).The safety of this treatment will also be studied","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants","timeFrame":"Baseline to Week 12","effectByArm":[{"arm":"Placebo Matching Dapagliflozin","deltaMin":-5.13,"sd":0.9489},{"arm":"Dapagliflozin 10 mg","deltaMin":-7.93,"sd":0.9357}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":6},"locations":{"siteCount":298,"countries":["United States","Australia","Canada","Colombia","Czechia","Denmark","Finland","Germany","Hungary","India","Ireland","Mexico","Poland","Puerto Rico","Romania","United Kingdom"]},"refs":{"pmids":["38770818","26620248"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":224},"commonTop":[]}}